Motif Bio to Present Iclaprim Data at ASM Microbe 2018

NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that two iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microbiology (ASM) Microbe 2018 meeting to be held in Atlanta, GA, USA, June 7-11, 2018.  The abstracts are now available online on the ASM website.

ASM Microbe showcases the best microbial sciences in the world and provides a forum to explore the complete spectrum of microbiology from basic science to translation and application.

An Analysis of Pooled Efficacy Data from Two Phase 3 Trials of Iclapr…


Leave a Reply

Your email address will not be published.